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Purpose: To compare the short-term effects of intravitreal versus posterior subtenon injection of triamcino-
lone acetonide for diabetic macular edema.
Methods: This is a prospective and interventional study. Sixty eyes of 60 patients who had diffuse diabetic 
macular edema were assigned to receive a single intravitreal injection (4 mg) or a single posterior subtenon 
injection (40 mg) of triamcinolone acetonide. The central retinal thickness was measured using optical 
coherent tomography before injection and at 1 and 3 months after injection. Visual acuity and intraocular 
pressure (IOP) were also measured. 
Results: Both intravitreal and posterior subtenon injections of triamcinolone acetonide resulted in significant 
improvements in visual acuity at 1 month and 3 months after injection. Both groups resulted in a significant 
decrease in central macular thickness (CMT) at 1 month and 3 months post-injection. IOP in the intravitreal 
injection group was significantly higher than in the posterior subtenon injection group at 3 months after 
injection.
Conclusions: The posterior subtenon injection of triamcinolone acetonide had a comparable effect to the 
intravitreal triamcinolone injection and showed a lower risk of elevated IOP. Posterior subtenon injection of 
triamcinolone acetonide may be a good alternative for the treatment of diffuse diabetic macular edema.  
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Diabetic macular edema is a common cause of visual loss 
in patients with diabetic retinopathy. It may occur by focal 
leakage from microaneurysms, which is often associated with 
intraretinal lipid deposition in a circinate pattern, and by 
diffuse leakage from the perifoveal retinal capillaries. In the 
Early Treatment Diabetic Retinopathy Study (ETDRS), focal 
laser photocoagulation was applied for leakages from the 
microaneurysms and grid laser photocoagulation was applied 
for areas of diffuse capillary leakage.
1,2 However, several 
studies have shown that eyes with diffuse macular edema 
carry a particularly poor prognosis despite laser photocoagu-
lation.
3,4 In the ETDRS,
1 only 17% of the eyes had any 
improvement in visual acuity and less than 3% had a visual 
improvement of 3 or more ETDRS lines.
In recent years, the intravitreal administration of triamcino-
lone acetonide has provided promising results for the treat-
ment of diffuse macular edema.
5-9 However, the risk of ocular 
complications such as intraocular pressure (IOP) elevation,
10-12 
endophthalmitis,
13 retinal detachment and glaucoma was 
reported.
Posterior subtenon injection of a steroid is an alternative 
method with proven effectiveness in various ocular diseases 
like cystoid macular edema and intermediate uveitis. 
Posterior subtenon injection of triamcinolone has also been 
reported to be an effective and safe treatment for diffuse 
diabetic macular edema.
14 
We performed a prospective study to compare effectiveness 
and safety between intravitreal and posterior subtenon injec-
tion of triamcinolone acetonide for the treatment of diffuse 
macular edema.
Materials and Methods
Sixty eyes of 60 patients with macular edema involving 
the fovea were enrolled in this study. Diffuse macular edema 
was defined by central thickening on a biomicroscopy using 
a 90-diopter noncontact lens and by diffuse fluorescein 
leakage on fluorescein angiography. Central macular thick-
ness (CMT) was required to be >250 μ m on an optical 
coherent tomography (OCT). Patients with other pathologies Korean  J  Ophthalmol  Vol.20,  No.4,  2006
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IVTA* PSBTA
†
between  two  groups
p  value Mean±SD p  value Mean±SD p  value 
Baseline
POD  1  mo
POD  3  mo
0.731±0.406
0.571±0.393
0.535±0.382
0.001
0.001
0.788±0.280
0.650±0.281
0.623±0.264
0.011
0.007
0.338
0.672
0.461
*IVTA:  intravitreal  triamcinolone  injection  group, 
†PSBTA:  posterior  subtenon  triamcinolone  injection  group.
Table 2. Visual  Acuity  (LogMAR)
of macula or optic disc such as glaucoma or ocular hyper-
tension were excluded. Patients with extensive foveal ischemia 
with more than one disc diameter of capillary closure on 
fluorescein angiography were excluded. Patients who had 
undergone intraocular surgery or macular grid laser photocoa-
gulation within 3 months prior to the injection were excluded.
One of the authors (K.H.) performed intravitreal injection 
and another (J.O.) performed posterior subtenon injection 
during the same period. The physicians who checked visual 
acuity, IOP and CMT had not been informed of the purpose 
of this study or the assignment schedule.
Intravitreal injection was done under sterile conditions in 
the operating room. Eyes receiving the intravitreal injection 
were anesthetized by topical instillation of 0.5% proparacaine 
hydrochloride. Under the operating microscope, 0.1 ml of 
triamcinolone acetonide (4 mg) was injected slowly via a 30- 
gauge needle through the pars plana, 3.0 mm posterior to the 
limbus in the pseudopakic eyes and 4.0 mm posterior to the 
limbus in phakic eyes. For the posterior subtenon injection, 
under topical anesthesia (0.5% proparacaine hydrochloride), 
a small incision (8 mm posterior to the limbus) was made 
through the superotemporal forniceal conjunctiva and tenon’s 
capsule to bare the sclera using Westcott scissors. The curved 
portion of the pinpoint cannula was inserted and a volume 
of 1 ml containing 40 mg triamcinolone was slowly injected 
behind the eye through the incision site. After the triam-
cinolone application was completed, the cannula was with-
drawn slowly, with gentle pressure maintained by a sterile 
swab along the path of the cannula. No drug reflux was 
observed. 
The patients were evaluated on the basis of central retinal 
thickness from OCT, visual acuity and IOP. All the patients 
underwent these examinations before injection and at 1 week, 
1 month and 3 months post-injection. During the OCT proce-
dure, each eye underwent six radial scans centered on the 
fovea. The value which printed on the OCT automated mode 
determined the central retinal thickness. The best-corrected 
visual acuity on the decimal charts was examined at each 
visit and was converted to the logarithm of minimal angle of 
resolution (logMAR) scale for statistical analysis. The IOP 
was measured using Goldmann applanation tonometry and 
the number of glaucoma medications used was recorded. 
The temporal changes in logMAR visual acuity, central 
retinal thickness and IOP were compared using the Wilcoxon 
signed rank test. The differences between groups in logMAR 
visual acuity, central retinal thickness, IOP and other contin-
uous variables were compared using the Mann-Whitney U 
test.
Results
The mean age of the patients (±SD) was 60.69±10.8 
years, with a range of 46 to 70 years. The mean (±SD) 
duration of diabetes was 16.3±8.1 years (range, 4-30 years). 
Patient demographics are shown in Table 1. No statistically 
significant differences were found between groups regarding 
age, gender, the ratio of left to right eyes, the ratio of PDR 
to NPDR or DM duration. 
IVTA* PSBTA
† p  value
No.  of  eyes
Mean  Age
Gender  (male / female)
Right / Left
PDR / NPDR
Phakic / Pseudophakic
DM  duration  (mean)
30
60.09±10.8
11 / 19
12 / 18
17 / 13
23 / 7
11.7
30
60.89±8.1
 9/2 1
14 / 16
17 / 13
22 / 8
13.4
-
0.362
0.520
0.398
0.561
0.505
0.477
*IVTA: intravitreal triamcinolone injection group, 
†PSBTA: posterior 
subtenon  triamcinolone  injection  group.
Table 1. Patient  Characteristics
Fig. 1. Visual  acuity  in  the  intravitreal  and  posterior  sub-tenon 
injected  eyes  at  baseline  and  at  1  and  3  months  after  triamcino-
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IVTA* PSBTA
†
between  two  groups
p  value Mean±SD p  value Mean±SD p  value 
Baseline
POD  1  mo
POD  3  mo
428.3±125.4
256.5±56.0
230.6±60.7
0.046
0.036
480.0±1235.4
318.4±136.5
271.1±89.8
0.043
0.026
0.461
0.273
0.795
*IVTA:  intravitreal  triamcinolone  injection  group, 
†PSBTA:  posterior  subtenon  triamcinolone  injection  group.
Table 3. Central  Macular  Thickness  (μ m)
A B
C D
Fig. 3. C h a n g e s  i n  t h e  O C T  i m a g e s  o f  r e p r e s e n t a t i v e  p a t i e n t  i n  t h e  i n t r a v i t r e a l  a n d  p o s t e r i o r  s u b t e n o n  i n j e c t i o n  g r o u p s .  I n  a n  e y e  t h a t 
underwent  intravitreal  injection,  the  marked  macular  edema  (A)  decreased  substan t i a l l y  a n d  t h e  e y e  s h o w e d  v i r t u a l l y  n o r m a l  m a c ular 
configuration at 3 months (B) after injection. In an eye that underwent posterior subtenon injection, the macular edema (C) also decreased 
substantially  with  time,  and  the  eye  showed  virtually  normal  macular  configuration  at  3  months  (D)  after  injection. 
Fig. 2. Central  macular  thickness  in  the  intravitreal  and  posterior 
subtenon  injected  eyes  at  baseline  and  at  1  and  3  months  after 
triamcinolone  acetonide  injection. 
The mean (±SD) visual acuity before triamcinolone aceto-
nide injection and at 1 week, 1 month and 3 months there-
after is shown in Table 2 and Fig. 1. The mean baseline visual 
acuity was not significantly different between the 2 groups 
(p=0.338). In both groups, the visual acuity significantly 
improved throughout the study. In the intravitreal injection 
group, the mean visual acuity at 1 month (0.571±0.393; p 
=0.001) and 3 months (0.535±0.382; p=0.001) after the 
injection were significantly better than baseline measure-
ments. In the posterior subtenon injection group, the mean 
visual acuity at 1 month (0.650±0.281; p=0.011) and 3 
months (0.623±0.264; p=0.007) after the injection was also 
significantly better than the baseline measurements. Between 
the 2 groups, there were no significant differences in the 
mean visual acuity changes before injection or at 1 month 
and 3 months after injection.
The mean baseline CMT was not significantly different Korean  J  Ophthalmol  Vol.20,  No.4,  2006
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IVTA* PSBTA
†
between  two  groups
p  value Mean±SD p  value Mean±SD p  value 
Baseline
POD  1  wk
POD  1  mo
POD  3  mo
16.36±2.17
16.00±2.76
17.80±3.47
18.44±3.76
0.513
0.229
0.072
16.46±2.04
16.48±2.01
16.76±2.28
16.28±2.23
0.497
0.527
0.292
0.524
0.323
0.362
0.026
*IVTA:  intravitreal  triamcinolone  injection  group, 
†PSBTA:  posterior  subtenon  triamcinolone  injection  group.
Table 4. Intraocular  Pressure  (mmHg)
Fig. 4. Intraocular pressure in the intravitreal and posterior  subtenon 
injected  eyes  at  baseline  and  at  1  and  3  months  after  triamcino-
lone  acetonide  injection. 
between the 2 groups (p=0.461). In both the intravitreal and 
posterior subtenon injection group, the CMT was significantly 
decreased through the study (Table 3, Fig. 2). At 3 months 
after injection, OCT demonstrated a reduction of the mean 
CMT (intravitreal group: 46.2%, subtenon group: 43.5%). 
Between the 2 groups, there was no significant difference in 
the mean CMT change before injection or at 1 month and 
3 months after injection. Fig. 3 illustrates the changes in the 
OCT images of a representative patient in the intravitreal 
injection group and of a patient in the posterior subtenon 
injection group.
The mean baseline IOP did not show differences between 
the 2 groups (p=0.524). In the intravitreal injection group, 
IOP tended to rise after the injection although the change was 
not statistically significant (Table 4, Fig. 4). Ten eyes (33%) 
experienced an IOP elevation to 21 mmHg or higher during 
the follow-up period. In the posterior subtenon injection 
group, a temporal change of IOP was not found. Only 1 eye 
(3.3%) experienced an IOP of 21 mmHg or higher during the 
follow up period. At 3 months after injection, the IOP change 
of the intravitreal injected eyes was greater than that of the 
posterior subtenon capsule injected eyes (p=0.026). 
Discussion
This study demonstrates that intravitreal injection or 
posterior subtenon injection has a beneficial effect in re-
ducing the diabetic macular edema. Two groups did not show 
any significant difference in visual acuity or mean CMT 
thickness improvement after injection. 
In this study, the change of mean visual acuity (LogMAR) 
after intravitreal injection was 0.160 (21.8%) at 1 month and 
0.196 (26.8%) at 3 months after the injection. The change of 
mean CMT was 171.6 μ m (40.1%) at 1 month and 197.7 μ m 
(46.2%) at 3 months after intravitreal injection. These results 
were similar to previous studies. Martidis et al.
5 reported that 
CMT decreased by 55% and 57.5% at 1 and 3 months after 
intravitreal trimcinolone injection, respectively. Ciardella et 
al.
8 reported decreases of 42% and 46.4%. Jonas et al.
9 
reported that visual acuity(LogMAR) improved by 0.15 
(15.3%) and 0.19 (19.3%) at 1 and 3 months after intravitreal 
trimcinolone injection, respectively.
Posterior subtenon injection of triamcinolone has been 
used with proven effectiveness in conditions with a breakdown 
in the blood-retinal barrier, such as cystoid macular edema 
and intermediate uveitis. Recently, Ohguro et al.
14 reported 
an observational case series indicating the effectiveness of 
posterior subtenon triamcinolone infusion in diffuse diabetic 
macular edema in eyes that had not responded to vitrectomy. 
Bakri et al.
15 also reported that visual acuities remained stable 
or improved over a 12-month period after posterior subtenon 
triamcinolone injections for refractory diabetic macular 
edema. These recent results have a general connection with 
our study. 
Freeman et al.
16 have shown by ultrasound B-scan that the 
superotemporal placement technique results in more accurate 
placement of steroids near the macula. Geroski et al.
17 
reported the usefulness of the transscleral pathway in deliv-
ering the drug to the retina. Weijtens et al.
18 reported that the 
intravitreal concentration of the steroid increased after its 
peribulbar injection. On the basis of these reports, it can be 
summarized that the injected triamcinolone is located on the 
subtenon macular area and its therapeutic concentration on 
the choroids or retina can be obtained through the transscleral 
pathway.
Cardillo et al.
19 compared intravitreal injection with posterior 
subtenon injection of triamcinolone in diabetic macular 
edema. They concluded that the intravitreal injection was 
more favorable than the posterior subtenon injection for the YJ  Choi,  et  al.  TRIAMCINOLONE  ACETONIDE  FOR  DIABETIC  MACULAR  EDEMA
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anatomic and functional aspects of improvement. Bonini-Filho 
et al.
20 also suggested that intravitreal injection may be more 
effective than posterior subtenon injection for the manage-
ment of refractive diffuse diabetic macular edema. These two 
studies differ from our results in that our study show that 
both intravitreal and posterior subtenon injections may be 
equally tolerated with a short-term performance. The study of 
Cardillo et al was informative in that two approaches were 
performed to each eye of the same patient with bilateral 
symmetric diffuse macular edema. However one limitation of 
the study was the relatively small sample size (12 patients). 
In Bonini-Filho et al’s study, the patients had refractive 
diabetic macular edema. Thus, their results cannot directly be 
compared to our results. 
One advantages of posterior subtenon administration is a 
lower risk of complication. IOP elevation is the most common 
complication after intravitreal triamcinolone injection.
10-12 
Although not statistically significant, IOP after intravitreal 
injection tended to rise in our study. At 3 months after 
injection, the change of IOP in the intravitreal injection group 
was greater than that of the posterior subtenon injection 
group. Other complications such as endophthalmitis and retinal 
detachment were also reported following intravitreal injection 
in other studies.
In conclusion, the short-term efficacy of the intravitreal 
injection and of the posterior subtenon injection of triamcino-
lone in diffuse diabetic macular edema was similar. The 
posterior subtenon injection was less invasive and safer than 
the intravitreal injection. Therefore, posterior subtenon injection 
of triamcinolone acetonide may be a good option for the 
treatment of diffuse diabetic macular edema. 
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